Unveiling the prognostic value of ARID3A in breast cancer through bioinformatic analysis
Objective: Identifying reliable prognostic markers for breast cancer is crucial for improving survival rates and reducing mortality. Recent studies highlight the AT-rich interactive domain-containing protein (ARID) family, particularly ARID3A, as influential in cancer progression, though its specifi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844025004049 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823856769046151168 |
|---|---|
| author | Wen-Run Cai Xu-Gang Sun Yue Yu Xin Wang Xu-Chen Cao Xiao-Feng Liu |
| author_facet | Wen-Run Cai Xu-Gang Sun Yue Yu Xin Wang Xu-Chen Cao Xiao-Feng Liu |
| author_sort | Wen-Run Cai |
| collection | DOAJ |
| description | Objective: Identifying reliable prognostic markers for breast cancer is crucial for improving survival rates and reducing mortality. Recent studies highlight the AT-rich interactive domain-containing protein (ARID) family, particularly ARID3A, as influential in cancer progression, though its specific role in breast cancer remains unclear. This study investigates ARID3A's expression, prognostic relevance, clinicopathological correlations, co-expression profiles, and protein-protein interactions in breast cancer. Methods: ARID3A mRNA and protein expression levels were analyzed using UALCAN, GEPIA databases, and immunohistochemistry from our hospital samples. Clinical prognostic parameters and survival data were examined through bioinformatics tools, including GEPIA, Bc-GenExMiner, and BEST. Subtype-specific expression and co-expression, particularly with REXO1, were evaluated using LinkedOmics, TIMER, and bc-GenExMiner. Functional enrichment analysis was conducted via LinkedOmics. Protein-protein interactions (PPI) were established using GeneMANIA and STRING, with validation through molecular docking using Cluspro. Results: Elevated ARID3A expression was associated with poor prognosis in breast cancer, particularly in Luminal and HER2-positive subtypes. A positive correlation with REXO1 was identified, and enrichment analysis emphasized ARID3A's involvement in immune-related pathways, such as “interferon gamma production” and “primary immunodeficiency.” PPI network and docking studies identified TP53 as a potential binding partner, suggesting a novel interaction influencing tumor progression. Conclusion: These findings indicate that ARID3A may serve as a prognostic biomarker and therapeutic target in breast cancer, providing insights into its involvement in oncogenic pathways and interactions, particularly with TP53, that may drive cancer development and progression. |
| format | Article |
| id | doaj-art-ba569699bbcc4562b2409e2f89e8356a |
| institution | Kabale University |
| issn | 2405-8440 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj-art-ba569699bbcc4562b2409e2f89e8356a2025-02-12T05:31:22ZengElsevierHeliyon2405-84402025-02-01114e42024Unveiling the prognostic value of ARID3A in breast cancer through bioinformatic analysisWen-Run Cai0Xu-Gang Sun1Yue Yu2Xin Wang3Xu-Chen Cao4Xiao-Feng Liu5The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, ChinaKey Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China; Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, ChinaThe First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, ChinaThe First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, ChinaThe First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, ChinaThe First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China; Corresponding author. The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, He-Xi District, Tianjin, 300060, China.Objective: Identifying reliable prognostic markers for breast cancer is crucial for improving survival rates and reducing mortality. Recent studies highlight the AT-rich interactive domain-containing protein (ARID) family, particularly ARID3A, as influential in cancer progression, though its specific role in breast cancer remains unclear. This study investigates ARID3A's expression, prognostic relevance, clinicopathological correlations, co-expression profiles, and protein-protein interactions in breast cancer. Methods: ARID3A mRNA and protein expression levels were analyzed using UALCAN, GEPIA databases, and immunohistochemistry from our hospital samples. Clinical prognostic parameters and survival data were examined through bioinformatics tools, including GEPIA, Bc-GenExMiner, and BEST. Subtype-specific expression and co-expression, particularly with REXO1, were evaluated using LinkedOmics, TIMER, and bc-GenExMiner. Functional enrichment analysis was conducted via LinkedOmics. Protein-protein interactions (PPI) were established using GeneMANIA and STRING, with validation through molecular docking using Cluspro. Results: Elevated ARID3A expression was associated with poor prognosis in breast cancer, particularly in Luminal and HER2-positive subtypes. A positive correlation with REXO1 was identified, and enrichment analysis emphasized ARID3A's involvement in immune-related pathways, such as “interferon gamma production” and “primary immunodeficiency.” PPI network and docking studies identified TP53 as a potential binding partner, suggesting a novel interaction influencing tumor progression. Conclusion: These findings indicate that ARID3A may serve as a prognostic biomarker and therapeutic target in breast cancer, providing insights into its involvement in oncogenic pathways and interactions, particularly with TP53, that may drive cancer development and progression.http://www.sciencedirect.com/science/article/pii/S2405844025004049ARID3ABreast cancerPrognosisBioinformaticsTP53 |
| spellingShingle | Wen-Run Cai Xu-Gang Sun Yue Yu Xin Wang Xu-Chen Cao Xiao-Feng Liu Unveiling the prognostic value of ARID3A in breast cancer through bioinformatic analysis Heliyon ARID3A Breast cancer Prognosis Bioinformatics TP53 |
| title | Unveiling the prognostic value of ARID3A in breast cancer through bioinformatic analysis |
| title_full | Unveiling the prognostic value of ARID3A in breast cancer through bioinformatic analysis |
| title_fullStr | Unveiling the prognostic value of ARID3A in breast cancer through bioinformatic analysis |
| title_full_unstemmed | Unveiling the prognostic value of ARID3A in breast cancer through bioinformatic analysis |
| title_short | Unveiling the prognostic value of ARID3A in breast cancer through bioinformatic analysis |
| title_sort | unveiling the prognostic value of arid3a in breast cancer through bioinformatic analysis |
| topic | ARID3A Breast cancer Prognosis Bioinformatics TP53 |
| url | http://www.sciencedirect.com/science/article/pii/S2405844025004049 |
| work_keys_str_mv | AT wenruncai unveilingtheprognosticvalueofarid3ainbreastcancerthroughbioinformaticanalysis AT xugangsun unveilingtheprognosticvalueofarid3ainbreastcancerthroughbioinformaticanalysis AT yueyu unveilingtheprognosticvalueofarid3ainbreastcancerthroughbioinformaticanalysis AT xinwang unveilingtheprognosticvalueofarid3ainbreastcancerthroughbioinformaticanalysis AT xuchencao unveilingtheprognosticvalueofarid3ainbreastcancerthroughbioinformaticanalysis AT xiaofengliu unveilingtheprognosticvalueofarid3ainbreastcancerthroughbioinformaticanalysis |